The purpose of this study is to evaluate the efficacy and safety of recombinant human B-type natriuretic peptide (rhBNP) on heart and renal function in patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI).
Patients with acute decompensated heart failure (ADHF) and acute renal injury (AKI) will be randomized to receive standard of care with or without additional rhBNP. Clinical heart function, LVEF, SCr, GFR and other laboratory parameters will be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
intravenous administration of rhBNP 0.01 µg/kg/min
standard of care for heart failure
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGleft ventricular systolic function
Time frame: 90 days
serum creatinine
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.